决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:A Living Archive of High-risk Lymphoma.
在本期《血液癌症发现》中,Yang及其同事展示了一个侵袭性大B细胞淋巴瘤患者来源异种移植模型的综合资源库。
在本期《Blood Cancer Discovery》中,Yang及其同事展示了一个侵袭性大B细胞淋巴瘤患者来源异种移植模型的综合资源库。这一公开可用的资源将接受多种现代疗法(包括CAR-T 细胞)治疗的个体疾病标本与其高风险临床治疗史以及肿瘤的分子和转录特征联系起来,使得研究肿瘤细胞内在的治疗耐药机制和对新疗法的易感性成为可能。参见Yang等人的相关文章,第829页。
In this issue of Blood Cancer Discovery, Yang and colleagues present a comprehensive repository of patient-derived xenograft models of aggressive large B-cell lymphoma. The publicly available resource links disease specimens from individuals treated with diverse modern therapies (including chimeric antigen receptor T cells) to their high-risk clinical treatment histories and the molecular and transcriptional characteristics of their tumors, enabling the study of tumor cell-intrinsic mechanisms of therapeutic resistance and susceptibility to novel therapies. See related article by Yang et al., p. 829.
MEMBER ACCOUNT
登录成功会直接打开下一页。